Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/1/1998 First Published: 5/1/1998


1.		Phase III Randomized Study of Neoadjuvant Androgen Deprivation Followed By Conformal Radiotherapy in Patients With Localized Prostate Cancer (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				Other				NCRI-1104 EU-98006, UKCCCR-1104

Last Modified: 2/23/2007 First Published: 1/1/1999


2.		Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				CAN-NCIC-PR7 SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7

Last Modified: 12/11/2003 First Published: 5/1/2000


3.		Phase III Randomized Study of Cyproterone Acetate in Patients With Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				Pharmaceutical / Industry				BARR-PCA-301 NCT00005623

Last Modified: 10/7/2008


4.		Phase III Immediate vs Delayed Endocrine Therapy with Zoladex and Cyproterone Acetate for Patients with pN1-3M0 Carcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								EORTC-30846

Last Modified: 9/22/2004


5.		Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 80								EORTC-22863

Last Modified: 9/1/1988


6.		Phase III Randomized Comparison of Orchiectomy vs Buserelin vs Buserelin/Cyproterone Acetate in Patients with Stage D Prostatic Carcinoma Previously Untreated with Chemotherapy or Endocrine Therapy (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				50 to 80								EORTC-30843

Last Modified: 1/24/2008


7.		Phase III Comparison of Early vs Delayed Endocrine Manipulation (Orchiectomy or LHRH Agonist Therapy) in Previously Untreated Patients with Nonmetastatic Asymptomatic Carcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				80 and under								EORTC-30891

Last Modified: 6/1/1990


8.		Phase III Comparison of Flutamide vs Cyproterone Acetate in Patients with Painless Metastatic Prostatic Adenocarcinoma with Favorable Prognostic Characteristics (Summary Last Modified 06/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								EORTC-30892


9.		A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Completed				18 and over				Other				PCA-201 NCT00196339

Last Modified: 11/15/2007


10.		Randomized Comparison of Orchiectomy vs DES vs Orchiectomy plus Cyproterone Acetate for Metastatic Prostatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				no age specified								EORTC-30805

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute